ERBB2 and breast carcinoma: Furthermore, among major subtypes of breast cancer, SD was observed in 2 of 4 patients with triple-negative, in 1 of 2 with Her2 positive, and in 1 of 2 ER+PR+Her2− tumors (Table 3), indicating that all major breast subtypes are sensitive to Elenagen.